Positive PIII results for VYXEOS revealed at ASCO

Building on the announcement made in March of this year, Celator Pharmaceuticals has today (June 4th) presented the Phase III (PIII) findings for its combination therapy VYXEOS (cytarabine and daun

What are the key presentations at ASCO 2016?

The 2016 American Society of Clinical Oncology (ASCO) annual meeting starts today (3rd June), and it promises to be packed with the latest data and trends from the world of oncology.

Available on demand: What's next for patient-centricity?

This webinar delved into the challenges that pharma face when looking at their patient-centricity strategy.

Possible new breast cancer use for AZ's Faslodex

‘Good enough’ digital marketing not an option for pharma

Pharma companies must analyse the user experience of their websites to ensure continued patient engagement, and review their digital strategy frequently.

Modernising strategies for monitoring clinical trials

Updating monitoring strategies and combining them with the latest technology can streamline clinical trial processes.